TEVA SETTLES PATENT CHALLENGE OF GSK DRUGS

Published Online: Thursday, November 1, 2007

Teva Pharmaceutical Industries Ltd has resolved its patent dispute with GlaxoSmithKline (GSK) via a settlement that will allow the Israel-based generic drug maker to enter the US market with its generic versions of 3 GSK diabetes drugs: Avandia (rosiglitazone maleate), Avandamet (rosiglitazone maleate and metformin HCl), and Avandaryl (rosiglitazone maleate and glimepiride) oral tablets. Although details of the settlement were held confidential by both parties, it was disclosed that Teva could begin US marketing of the GSK drugs late in the first quarter of 2012. GSK filed several lawsuits challenging Teva?s plans to market generic versions of its drugs, and a trial in federal court had been scheduled to begin in August.




Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues
$auto_registration$
VSEO N/A